Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
Details : Renazorb (Lanthanum Dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology. it is being developed for the treatment of hyperphosphatemia in patients with chronic kidney ...
Brand Name : Renazorb
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 28, 2022
Lead Product(s) : Lanthanum Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?